Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/2021
Title: Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70)is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
Epworth Authors: Prince, Miles H.
Other Authors: Leleu, Xavier
Beksac, Meral
Chou, Takaaki
Dimopoulos, Meletios
Yoon, Sung-Soo
Pour, Ludek
Shelekhova, Tatiana
Chari, Ajai
Khurana, Monica
Zhang, Jianqi
Obreja, Mihaela
Qi, Ming
Oriol, Albert
Siegel, David
Keywords: Carfilzomib
Daratumumab
Multiple Myeloma
Dexamethasone (KdD)
Relapsed/Refractory Multiple Myeloma
Randomized Phase 3 CANDOR Study
Phase 1 b EQUULEUS Study
Immunomodulatory Imide Drugs (IMiDs)
Lenalidomide
Carfilzomib
Overall Response Rate (ORR)
Minimal Residual Disease (MRD)
Progression-Free Survival (PFS)
Inverse Probability of Treatment Weighting (IPTW)
Lenalidomide-Free Regimen
Convenient Dosing Option
EQUULEUS studies
CASTOR study
Hazard Ratios
Independent Review Committee (IRC)
Kaplan-Meier
Epworth Centre for Immunotherapies and Snowdome Laboratories
Molecular Oncology and Cancer Immunology
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Oct-2020
Publisher: National Center for Biotechnology Information (NCBI)
Citation: Leuk Lymphoma. 2021 Feb;62(2):358-367.
Abstract: The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m2 carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m2 carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). We analyzed efficacy data from comparable CANDOR and EQUULEUS patients using inverse probability of treatment weighting (IPTW)–adjusted models. These weights were calculated from propensity scores derived to balance prespecified baseline covariates. The side-by-side and adjusted comparisons showed similar efficacy for overall response rates and progression-free survival in the two groups, with a series of sensitivity analyses showing consistent findings. Safety data were generally consistent with the known safety profiles of each individual drug. Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety while being a more convenient dosing option. In conclusion, this cross-study analysis showed that once-weekly KdD70 in the EQUULEUS study is comparable to the twice-weekly KdD56 regimen used in the pivotal phase 3 CANDOR trial in terms of efficacy and safety. The weekly KdD70 dosing option addresses an important need for patients by providing a more convenient lenalidomide-free regimen that may encourage adherence and potentially lead to improved outcomes for patients.
URI: http://hdl.handle.net/11434/2021
DOI: 10.1080/10428194.2020.1832672
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/33112184/
ISSN: 1042-8194
1029-2403
Journal Title: Leukemia & Lymphoma
Type: Journal Article
Affiliated Organisations: Service d'Hématologie et Thérapie cellulaire, CHU and Inserm, Poitiers, France
Department of Hematology, Ankara University, Ankara, Turkey
Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
Department of Internal Medicine, Seoul National University, Seoul, South Korea
Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
Clinic of Professional Pathology, Saratov, Russian Federation
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Clinical Development, Oncology, Amgen Inc., Thousand Oaks, CA, USA
Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.
Hematology and Oncology, Janssen Research and Development, LLC, Spring House, PA, USA
Institut Català d'Oncologia and Josep Carreras Research Leukaemia Institute, Hospital Germans Trias i Pujol, Barcelona, Spain
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
Type of Clinical Study or Trial: Cross-Study Analysis
Appears in Collections:Cancer Services
MOCI

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.